Reuters logo
BRIEF-Aerie Pharmaceuticals provides update on timing of NDA filing for Rhopressa
December 23, 2016 / 11:51 AM / 9 months ago

BRIEF-Aerie Pharmaceuticals provides update on timing of NDA filing for Rhopressa

Dec 23 (Reuters) - Aerie Pharmaceuticals Inc

* Aerie now expects to resubmit Rhopressa(TM)NDA filing near end of Q1 of 2017

* Florida facility will not be ready for pre-approval inspection by FDA until end of February 2017

* Aerie Pharmaceuticals Inc - Delay does not result from any new findings, but rather additional time needed to complete validation of new equipment

* Aerie Pharmaceuticals provides update on timing of NDA filing for Rhopressatm (netarsudil ophthalmic solution) 0.02% Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below